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At present, one of the most critical problems for patients with type 2 diabetes mellitus 
(T2DM) is digestive organ cancers which are now considered a major cause of death. 
The risk of hepatocellular carcinoma (HCC), in particular, is approximately four times 
greater in diabetics compared to non-diabetic individuals.1 Nonalcoholic fatty liver 
disease (NAFLD), including nonalcoholic steatohepatitis (NASH), appears to play a 
significant role in T2DM-related hepatocarcinogenesis, but the detailed underlying 
pathological mechanism remains to be clarified.2 One would assume that individuals 
with T2DM and NAFLD should at least be closely followed up as high-risk patients. 
But, is this sufficient as a strategy in the care of T2DM patients? 
Recently we encountered a case of a ruptured HCC associated with T2DM. We 
report herein the case, to alert and activate discussion about current and future strategies 
for T2DM-related HCC. A 52-year-old man was urgently admitted to our hospital 
because of intra-abdominal hemorrhage. Imaging detected a 50mm tumor in the right 
lobe of the liver (Fig. 1A), and a clinical diagnosis of a ruptured HCC was made. 
Embolization was immediately performed and controlled the bleeding successfully. 
In the previous 2 years, the patient had been treated for T2DM and hypertension 
with metformin, linagliptin and amlodipine. His body mass index was 24kg/m2 and 
waist circumference was 84cm. He was not a habitual drinker. Serum markers of 
hepatitis viruses and autoantibodies were negative, liver function tests had never been 
abnormal, and he had no history of chronic liver disease or tumor (Fig. 1B). 
Three weeks after admission, the liver tumor was surgically removed (Fig. 1C).  
Histological examination showed complete coagulative necrosis (Fig. 1D), but the 
tumor could still be recognized as HCC (Fig. 1E). The background liver was 
non-cirrhotic and had steatosis in <5% hepatocytes (Fig. 1F), minimal acinar 
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inflammation, and rare typical ballooned hepatocytes (Fig. 1H) containing 
Mallory-Denk bodies (MDB) (Fig. 1I). There was only zone 3 sinusoidal fibrosis (Fig. 
1G). Based on the currently accepted NAFLD/NASH histological criteria,3,4 a diagnosis 
of steatohepatitis could not be made because of the absence of “significant” steatosis. 
However, the additional presence of hepatocyte ballooning with MDB and typical zone 
3 sinusoidal fibrosis supported our final clinicopathological diagnosis of HCC 
associated with “resolving NASH”. The antidiabetic drugs might have alleviated 
steatosis and disease activity, and the overall histological picture in the background liver 
represented NASH resolution.5 
Presence of fat droplets in 5% of hepatocytes is currently approved as the threshold 
for the histological diagnosis of pathological fat accumulation in liver tissue,3,4 and is 
possibly the lowest level detectable with modern imaging devices. However, strictly 
adhering to this criterion for diagnosing steatosis entails the risk of missing the 
diagnosis of NAFLD/NASH and related complications. It is important to recognize that 
diabetes-related “NAFLD/NASH”, especially in treated patients, may present with a 
non-pathologic level (<5%) of steatosis and that HCC can develop asymptomatically, 
like a silent killer, in non-cirrhotic liver. Eventually, all diabetic patients need close 
follow-up with regular imaging examinations to possibly detect T2DM-related HCCs at 
an early stage. 
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Figure legends 
Figure 1  The patient’s present and past radiological findings (A,B) and pathologic 
findings from the resected liver (C-I).  (A) Magnetic resonance image (T2 weighted) 
on admission. A round tumor with a mosaic internal structure (ø50 mm; arrow) is 
evident in the right hepatic lobe.  (B) Computed tomography (plain) 15 months before 
admission. No specific findings, including tumor or steatosis, can be detected.  (C) 
Cut-surface of the specimen. A brown, well-circumscribed tumor (ø50 mm) is shown.  
(D,E) Histologically, the tumor was necrotic but still recognizable as HCC (D, 
Hematoxylin-eosin stain, original magnification x280; E, Immunostain for HepPar1, 
original magnification x400).  (F,G) Background liver tissue shows minimal steatosis, 
mild acinar inflammation, and zone 3 sinusoidal fibrosis (F, Hematoxylin-eosin stain, 
original magnification x60; G, Azan-Mallory stain, original magnification x60).  (H,I) 
Rare presence of ballooned hepatocytes (H, Hematoxylin-eosin stain, original 
magnification x400) and MDB in the non-neoplastic liver (I, Immunostain for p62, 
original magnification x400). 
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